Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating for Lexeo Therapeutics, maintaining a price target of $23.
October 30, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Lexeo Therapeutics, maintaining a price target of $23.
The reaffirmation of a Buy rating and a specific price target by Chardan Capital is a positive signal for investors, suggesting confidence in Lexeo Therapeutics' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100